Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial (TOSCA IT)

Clinical Trial ID NCT00700856

Rank	Title	Journal	Year	PubWeight™‹?›
1	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.	Diabetes Metab Syndr Obes	2014	1.05
2	The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes.	Diabetes Care	2012	0.81
3	Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.	Diabetes Ther	2016	0.79
4	Current perspectives on cardiovascular outcome trials in diabetes.	Cardiovasc Diabetol	2016	0.79
5	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.	Nutr Metab Cardiovasc Dis	2012	0.78
6	Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes - The TOSCA.IT study.	Nutr Metab Cardiovasc Dis	2016	0.75
7	Cardiovascular effects of anti-diabetes drugs.	Expert Opin Drug Saf	2016	0.75
8	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.	Herz	2016	0.75
9	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.	Clin Pharmacol Ther	2015	0.75
10	Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study.	Clin Nutr	2016	0.75